Potassium Sorbate vs Advantame: which is worse?

What is Potassium Sorbate?

Potassium sorbate is the potassium salt of sorbic acid, a naturally occurring short-chain fatty acid originally derived from the mountain ash berry (Sorbus aucuparia). Commercial potassium sorbate is synthetically produced by reacting sorbic acid with potassium hydroxide. It is the most widely used food preservative globally.

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

Documented risks

Potassium Sorbate: Potassium sorbate has a generally good safety profile compared to other synthetic preservatives. EFSA's 2015 re-evaluation maintained the ADI at 3 mg/kg body weight, finding no significant carcinogenicity or genotoxicity. However, some human and in vitro studies have documented concerns. A 2010 study in Toxicology in Vitro found potassium sorbate was genotoxic (caused DNA strand breaks) in human blood cells at concentrations achievable in food. The study found it damaged peripheral blood lymphocytes. A 2014 study in Food and Chemical Toxicology found potassium sorbate caused DNA damage in human lymphocytes at food use concentrations. Contact dermatitis and allergic reactions from topical use are documented. At very high doses in animal studies, liver and kidney effects have been observed. The general regulatory consensus is that potassium sorbate is one of the safer food preservatives, but the in vitro genotoxicity findings deserve attention.

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.